

Dermatology Oral/Topical Enrollment Form

Prescriber:	NPI:
Supervising Physician:	NPI:
Address:	Tax ID:

		Physician 355-460-79	Offices Call:	Address:				Tax ID:			
Specialty Pharmacy		Fax: 888-7		Phone: Fax:							
3712 E. Plano Parkway, Ste. 200 Plano, TX 75074				Contact:							
This prescription form is t	o be sent & received via fax			PATIENT INFOR	MATION						
Name:				Trans M Trans F Other DOB:				SS#:	SS#:		
Street:			City:		State:			ZIP:			
Phone:	□ English	☐ <sub>Spanish</sub>	Other:		Wt.: Ht.:						
PRESCRIPTION											
Has the patient received a loading dose/starter kit? Yes Start Date://											
Litfulo™	50mg Capsule	☐ Take 50 mg PO once daily (Quantity: 28)									
Olumiant <sup>®</sup>	□ <sub>2 mg Tablet</sub>	□ <sub>Tak</sub>	Take 2 mg PO once daily (Quantity: 30)								
	□ <sub>4 mg</sub> Tablet	□ <sub>Tak</sub>	Take 4 mg PO once daily (Quantity: 30)								
	☐ 28 Day Starter Pack	□ <sub>Tak</sub>	Take as directed per package instructions (Quantity: 55)								
Otezla®	□ 30 mg Tablet □ Take 30 mg PO twice daily (Quantity: 60)										
Sotyktu™	6 mg Tablet										
Opzelura®	1.5 % Cream 60 gm										
Vtama®	1% Cream 60 gm	□ <sub>App</sub>	oly a thin layer to a	ffected area(s) onc	e a day (Qua	intity: 1 tube)					
***DI E	ASE FAX COPY OF PRE	SCRIPTION		MEDICAL INFOR		L AS ANY CLINIC	AL NOTES	PEGAPOING THEPAD	V***		
PREVIOUS THER				olerated:	Contrainc		AL NOTES		<u>.                                    </u>		
☐ Methotrexate			)								
☐ Soriatane			)						\		
☐ Clobetasol			)						W.		
□ <sub>Stelara</sub>			)								
□ <sub>Humira</sub>			)								
□ <sub>Enbrel</sub>	□ (		)					Affected Areas			
<u> </u>			)				Face	☐ Feet ☐ Groin	☐ <sub>Hands</sub>		
PHOTOTHERAPY	Tried & Fa	iled (Durat	ion): Not T	olerated:	Contraind	lication:	Nails	Scalp Other:			
□ UVA /UVB			)			BS	SA%		LT Score:		
☐ Patient can		osensitivity	☐Risk of Sk	kin Cancer D D	istance from		ate of Diag	nosis://	_		
□ L20.9 Atopic Dermatitis □ L40.0 Psoriasis Vulgaris (Plaque Psoriasis) Allergies:											
L63.9 Alopecia a	areata, unspecified		☐ L80 Vitiligo								
Other:			-								
Active TB ruled out:		11	Hep B ruled or	ut/treated:	□ <sub>No Date</sub>	e://					
Additional officer	miomaton.										
American Academy (f.D											
American Academy of Dermatology Consensus Statement on Psoriasis Therapies  Psoriasis is covering greater than 10% of body surface area Psoriasis is on palms, soles, head and neck, or genitalia Psoriasis occurs in conjunction with pain, swelling, or stiffness in joints											
Psoriasis patient needs more aggressive therapy due to impact on ability to perform daily activities, employment or interpersonal relationships  PRESCRIBER SIGNATURE											
To Prescriber By signir assistance foundations.	ng this form and utilizing our serv	vices, you are al				signated agent in dealing	with medical a	nd prescription insurance comp	anies, and co-pay		
Prescriber:							Date:				
			_	CALCIDENTIALIT	V NOTICE		<u> </u>				

CONFIDENTIALITY NOTICE

IMPORTANT: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, proprietary or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.